1-7 of 7
Atsumi Yamaguchi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling

Kazuhiko Yamada, Yusaku Hori, Satoshi Inoue, Yuji Yamamoto, Kentaro Iso, Hiroshi Kamiyama, Atsumi Yamaguchi, Takayuki Kimura, Mai Uesugi, Junichi Ito, Masahiro Matsuki, Kazutaka Nakamoto, Hitoshi Harada, Naoki Yoneda, Atsushi Takemura, Ikuo Kushida, Naomi Wakayama, Kenji Kubara, Yu Kato, Taro Semba, Akira Yokoi, Masayuki Matsukura, Takenao Odagami, Masao Iwata, Akihiko Tsuruoka, Toshimitsu Uenaka, Junji Matsui, Tomohiro Matsushima, Kenichi Nomoto, Hiroyuki Kouji, Takashi Owa, Yasuhiro Funahashi, Yoichi Ozawa
Journal: Cancer Research
Series: Author Choice
Cancer Res (2021) 81 (4): 1052–1062.
https://doi.org/10.1158/0008-5472.CAN-20-0782
Published: 15 February 2021
View article titled, E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling
Open the PDF for E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling in another window
Includes: Supplementary data
Journal Articles

Abstract 5177: E7386 : First-in-class orally active CBP/beta-catenin modulator as an anticancer agent

Kazuhiko Yamada, Yusaku Hori, Atsumi Yamaguchi, Masahiro Matsuki, Shuntaro Tsukamoto, Akira Yokoi, Taro Semba, Yoichi Ozawa, Satoshi Inoue, Yuji Yamamoto, Kentaro Iso, Kazutaka Nakamoto, Hitoshi Harada, Naoki Yoneda, Atsushi Takemura, Masayuki Matsukura, Kenji Kubara, Takenao Odagami, Masao Iwata, Akihiko Tsuruoka, Toshimitsu Uenaka, Junji Matsui, Tomohiro Matsushima, Kenich Nomoto, Hiroyuki Kouji, Takashi Owa
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5177.
https://doi.org/10.1158/1538-7445.AM2017-5177
Published: 01 July 2017
View article titled, Abstract 5177: E7386 : First-in-class orally active CBP/beta-catenin modulator as an anticancer agent
Journal Articles

Abstract 3264: Lenvatinib in combination with everolimus demonstrated enhanced antiangiogenesis and antitumor activity in human RCC xenograft models

Yusuke Adachi, Masahiro Matsuki, Atsumi Yamaguchi, Yoichi Ozawa, Kiyochi Okamoto, Kaoru Mitsuhashi, Takayuki Kimura, Taisuke Hoshi, Osamu Tohyama, Kenji Tai, Makoto Ogo, Yasuhiro Funahashi, Junji Matsui
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3264.
https://doi.org/10.1158/1538-7445.AM2016-3264
Published: 15 July 2016
View article titled, Abstract 3264: Lenvatinib in combination with everolimus demonstrated enhanced antiangiogenesis and antitumor activity in human RCC xenograft models
Journal Articles

Abstract 3262: Effects of lenvatinib mesilate in combination with everolimus on VEGF and FGF-driven angiogenesis and tumor growth

Kaoru Mitsuhashi, Takayuki Kimura, Taisuke Hoshi, Osamu Tohyama, Kenji Tai, Makoto Ogo, Masahiro Matsuki, Atsumi Yamaguchi, Yoichi Ozawa, Yusuke Adachi, Kiyoshi Okamoto, Junji Matsui, Yasuhiro Funahashi
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3262.
https://doi.org/10.1158/1538-7445.AM2016-3262
Published: 15 July 2016
View article titled, Abstract 3262: Effects of lenvatinib mesilate in combination with everolimus on VEGF and FGF-driven angiogenesis and tumor growth
Journal Articles

E7050: a novel small molecule inhibitor of the c-Met and VEGFR-2 tyrosine kinases

Hiroshi Obaishi, Takayuki Nakagawa, Atsumi Yamaguchi, Osamu Tohyama, Tomohiro Matsushima, Keiko Takahashi, Setsuo Funasaka, Shuji Shirotori, Makoto Asada
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 4846.
Published: 01 May 2008
View article titled, E7050: a novel small molecule inhibitor of the c-Met and VEGFR-2 tyrosine kinases
Journal Articles

E7050: A novel orally active c-Met and VEGFR-2 tyrosine kinase inhibitor exhibited potent antitumor effect and prolongation of survival in preclinical mice model

Takayuki Nakagawa, Hiroshi Obaishi, Atsumi Yamaguchi, Osamu Tohyama, Tomohiro Matsushima, Keiko Takahashi, Setsuo Funasaka, Shuji Shirotori, Makoto Asada
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 4845.
Published: 01 May 2008
View article titled, E7050: A novel orally active c-Met and VEGFR-2 tyrosine kinase inhibitor exhibited potent antitumor effect and prolongation of survival in preclinical mice model
Journal Articles

Mechanism of Action of E7010, an Orally Active Sulfonamide Antitumor Agent: Inhibition of Mitosis by Binding to the Colchicine Site of Tubulin

Kentaro Yoshimatsu, Atsumi Yamaguchi, Hiroshi Yoshino, Nozomu Koyanagi, Kyosuke Kitoh
Journal: Cancer Research
Cancer Res (1997) 57 (15): 3208–3213.
Published: 01 August 1997
View article titled, Mechanism of Action of E7010, an Orally Active Sulfonamide Antitumor Agent: Inhibition of Mitosis by Binding to the Colchicine Site of Tubulin
Open the PDF for Mechanism of Action of E7010, an Orally Active Sulfonamide Antitumor Agent: Inhibition of Mitosis by Binding to the Colchicine Site of Tubulin in another window